

AMENDMENTS TO THE CLAIMS:

The present listing of the claims will replace all previous claim listings as follows:

1. (Currently amended) A device for urinary catheteriszation comprising a catheter element adapted for intermittent catheteriszation ~~to be inserted in~~ of the urethra of a human, said catheter element ~~comprising~~ having on ~~the~~ its outer surface, ~~before~~ prior to insertion of the catheter element, a pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, ~~such that the~~ and said pharmaceutically active composition is delivered to the lower urinary tract ~~system~~ during catheteriszation.

2. (Currently amended) A The device according to claim 1, wherein said pharmaceutically active composition comprises a hormone.

3. (Currently amended) A The device according to claim 1, said

device being provided in a sealed package, wherein a ~~major part~~
substantial amount of said pharmaceutically active composition is
present on an the outer surface of the catheter element.

4. (Currently amended) A The device according to claim 1, wherein
the pharmaceutically active composition is distributed over a
section of the catheter element having a length of at least 50% of
the total length of the catheter element.

5. (Cancelled).

6. (Currently amended) A The device according to claim 1, wherein
said catheter element ~~is~~ compriseds ~~in~~ a female catheter.

7. (Currently amended) A The device according to claim 1, wherein
said catheter element has a coating covering at least a portion of
the outer surface of the catheter element and said coating contains
at least a ~~part~~ portion of said pharmaceutically active
composition, and is adapted to release said pharmaceutically active
composition within the lower urinary tract ~~system~~.

8. (Currently amended) A The device according to claim 1, wherein

at least a part of said catheter element has a polymer coating, and at least a portion of said polymer coating is impregnated with at least a part of said pharmaceutically active composition.

9. (Currently amended) A The device according to claim 1, wherein at least a portion of said catheter element ~~has~~ further comprises a hydrophilic polymer coating.

10. (Currently amended) A The device according to claim 9, wherein said hydrophilic polymer coating is impregnated with at least a ~~part~~ portion of said pharmaceutically active composition.

11. (Currently amended) A The device according to claim 1, wherein said catheter element ~~has~~ further comprises at least one or more depressions on the outer surface, wherein said depressions ~~which are adapted to hold~~ are capable of containing at least a ~~part~~ portion of said pharmaceutically active composition.

12. (Currently amended) A The device according to claim 1, wherein at least a ~~part~~ portion of said pharmaceutically active composition is provided in a gel or ~~exème~~ cream formulation.

13. (Currently amended) A The device according to claim 1, wherein said device ~~is~~ further comprising a lubricating gel adapted to reduce friction between the catheter element and urethra, and said gel ~~is containing~~ contains at least a ~~part~~ portion of said pharmaceutically active composition.

14. (Currently amended) A The device according to claim 1, wherein said device ~~is comprising~~ a discrete unit dose containing said pharmaceutically active composition, and said device is adapted to ~~shed~~ deliver said discrete unit dose in the lower urinary tract system.

15. (Currently amended) A The device according to claim 1, wherein said hormone is a female sex hormone or a derivative thereof.

16. (Currently amended) A The device according to claim 15, wherein said hormone is selected from oestrogen or an oestrogen derivative.

17. (Currently amended) A The device according to claim 15, wherein said hormone is oestriol or oestradiol.

18. (Currently amended) A The device according to claim 1, wherein

said pharmaceutically active composition comprises an efferent blocking agent selected from the group consisting of anti-cholinergical agents, sympathomimetics agents, alfa-adrenergic agonists and nicotinic cholinergic agonists.

19. (Currently amended) A The device according to claim ~~19~~ 18, wherein said efferent agent is oxybutynin or trospiumchlorid.

20. (Currently amended) A The device according to claim 1, wherein said pharmaceutically active composition comprises an afferent blocking agent.

21. (Currently amended) The use of a pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, for the manufacture of a device for the treatment, alleviation or prophylaxis of incontinence in a human, said device comprising a catheter element adapted for intermittent catheterization ~~to be inserted in~~ of the urethra of a human, said catheter element ~~comprising~~ having the pharmaceutically active composition, and said catheter element being adapted to deliver said agent in the lower urinary tract ~~system~~ during

catheteriszation.

22. (Original) The use according to claim 21, wherein the human is a female.

23. (Currently amended) The use according to claim 21, wherein the device is ~~as defined in a device~~ for urinary catheteriszation comprising a catheter element adapted for intermittent catheterization ~~to be inserted in~~ of the urethra of a human, said catheter element ~~comprising~~ having on the outer surface, ~~before~~ prior to insertion of the catheter element, a pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, ~~such that~~ and wherein the pharmaceutically active composition is delivered to the lower urinary tract ~~system~~ during catheteriszation.

24. (Currently amended) A method of treating a human suffering from or being susceptible to incontinence, the method comprising the steps of catheteriszation of said human by arranging a proximal end of a catheter element of a device adapted for intermittent urinary catheteriszation in the urethra of said human, said catheter

element comprising a pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, and said catheter element being adapted to deliver said composition into the lower urinary tract ~~system~~ of said human during catheteriszation.

25. (Original) The method according to claim 24, wherein the human is a female.

26. (Currently amended) The method according to claim 23, wherein the device is ~~as defined in a~~ device for urinary catheteriszation comprising a catheter element adapted for intermittent catheterization ~~to be inserted in~~ of the urethra of a human, said catheter element ~~comprising~~ having on the outer surface, before insertion of the catheter element, a pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, ~~such that~~ wherein the pharmaceutically active composition is delivered to the lower urinary tract ~~system~~ during catheteriszation.

27. (Currently amended) A kit comprising a device for urinary catheteriszation and a pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, said device comprising a catheter element adapted for intermittent catheterization ~~to be inserted in~~ of the urethra of a human.

28. (Currently amended) A device for urinary catheteriszation, said device comprising a catheter element adapted for intermittent catheterization with a proximal end adapted to be inserted into a urinary canal of a human, ~~characterised in that wherein~~ said device ~~is comprising~~ contains a discrete unit dose, said discrete unit dose ~~comprising~~ contains a pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, and said catheter element being adapted to ~~shed~~ deliver said pharmaceutically active composition in the lower urinary tract ~~system~~ during catheteriszation.

29. (Currently amended) A The device according to claim 28, wherein said discrete unit dose is placed at the ~~tip~~ distal end of the

USSN 10/538,832
Atty Dkt No. P68468US1

catheter.